|Bid||23.13 x 1000|
|Ask||23.16 x 800|
|Day's Range||22.68 - 23.30|
|52 Week Range||17.20 - 28.45|
|Beta (3Y Monthly)||2.18|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would wait for Arista Networks Inc (NYSE: ANET ) to come down before buying the stock. Cramer likes NVIDIA (NASDAQ: NVDA ). He loves ...
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
The spinoff provides a valuable framework to value Bausch Health’s Bausch+Lomb, one which shows the inherent upside to a separation of the businesses, Mizuho analyst Irina Koffler says.
According to the GuruFocus All-in-One Screener, the following companies have high business predictability ratings and a wide margin of safety. The company has a three out of five-star business predictability rank and, according to the discounted cash flow calculator, a 75.47% margin of safety at $25 per share. Warning! GuruFocus has detected 5 Warning Signs with BHC.
Bausch Health Companies Inc NYSE:BHCView full report here! Summary * Perception of the company's creditworthiness is positive and improving * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BHC. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BHC are favorable with net inflows of $26.88 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator with a strengthening bias over the past 1-month. BHC credit default swap spreads are decreasing and near the lowest level of the last three years, which indicates improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
LAVAL, Quebec , April 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its first-quarter 2019 financial results on Monday, May 6, 2019 . Bausch ...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Shipments to U.S. Pharmaceutical Distributors Begin BRIDGEWATER, N.J. , April 2, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies ...
Investigational Treatment Demonstrated Promising Results in Preclinical Studies BRIDGEWATER, N.J. , April 1, 2019 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), one of the largest specialty ...
Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.
What Analysts Think about These Generic Pharmaceutical StocksAnalysts’ recommendations and target price Wall Street analysts expect an upside potential of 24.28% for Bausch Health Companies (BHC) based on the company’s closing price on March 22.
Bausch Health Companies Inc’s (NYSE: BHC ) growth drivers will become “more tangible” in 2019, and shares could appreciate as the company continues to demonstrate good execution, according to Mizuho Securities. ...
Inc. won court permission to move forward with the second phase of its bankruptcy, winding down what remains of the company following the sale of its assets. In the U.S. Bankruptcy Court in New York Tuesday, Judge James Garrity Jr. approved a blueprint of the company’s wind-down plan, which will soon be sent out to creditors for a vote. Court papers show creditors have until April 11 to cast their ballots. Synergy hopes to win final approval of the plan, which splits the remaining sale proceeds between junior and senior lenders, at another hearing scheduled for April 23. Under the plan, unsecured creditors are guaranteed to take home at least $13 million as well as a chance to share in the proceeds resulting from future lawsuits.
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. For example,Read More...
LAVAL, Quebec, March 11, 2019 /PRNewswire/ -- Ortho Dermatologics, one of the largest prescription dermatology health care businesses, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced the opening of applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total in scholarships to nine students who have been treated for a dermatologic condition. "At Ortho Dermatologics, our passion for dermatology is fueled by our understanding of the tremendous impact the profession can have on patients' lives," said Bill Humphries, president, Ortho Dermatologics.